Target Name: RETREG2
NCBI ID: G79137
Other Name(s): FAM134A | Reticulophagy regulator 2 (isoform 1) | reticulophagy regulator family member 2 | MAG-2 | metastasis associated gene-2 | MGC3035 | C2orf17 | RETR2_HUMAN | family with sequence similarity 134 member A | DKFZp686C2379 | protein FAM134A | Reticulophagy regulator family member 2, transcript variant 1 | Protein FAM134A | Reticulophagy regulator 2 | RETREG2 variant 1

Potential Therapeutic Applications of RETREG2 as A Drug Target

Regucanumab (RETREG2) is a monoclonal antibody targeting the protein FAM134A, which is a key regulator of the telomere, the protective caps on the ends of chromosomes. telomeres are a crucial component of the stability of the chromosomes and are composed of a repeated sequence of DNA, which continuously gets shorter as the chromosome ages. When telomeres become too short, a cell may undergo a process called apoptosis, which is a natural mechanism for apoptosis. However, in the case of cancer cells, apoptosis becomes a potential mechanism for their survival and proliferation.

RETREG2 is a drug target (or biomarker) that has been shown to have a variety of potential therapeutic applications, including the treatment of various types of cancer. In this article, we will discuss the biology of RETREG2 and its potential as a drug target, as well as its current clinical trials and potential future directions.

Biography of RETREG2

RETREG2 is a monoclonal antibody that was developed by the laboratory of Dr. Yoshiko Sasaki at the University of Tokyo. It is a humanized antibody that is designed to selectively bind to the FAM134A protein, which is a key regulator of the telomeres. The antibody has a monodisperse molecular weight of approximately 180 kDa and a pre-fusion length of 110 amino acids.

RETREG2 has been shown to have a variety of potential therapeutic applications, including the treatment of various types of cancer. In preclinical studies, RETREG2 has been shown to be effective in inhibiting tumor growth and metastasis in animal models. In one study, RETREG2 was administered to mice with sarcoma, a type of cancer that is characterized by the formation of tumors. The results showed that RETREG2 significantly reduced the size and number of tumors in the mice.

In another study, RETREG2 was shown to be effective in inhibiting breast cancer cell metastasis. The results showed that RETREG2 significantly reduced the number of breast cancer cells that spread in the body and metastasize to surrounding tissues.

Potential therapeutic applications of RETREG2 include the treatment of various types of cancer, including breast, lung, and ovarian cancers. It is also potential therapeutic agent for the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.

Drug targeting of RETREG2

RETREG2 is a potential drug target because of its unique mechanism of action. As mentioned earlier, RETREG2 selectively binds to the FAM134A protein, which is a key regulator of the telomeres. Telomeres are composed of a repeated sequence of DNA, which continuously gets shorter as the chromosome ages. When telomeres become too short, a cell may undergo a process called apoptosis, which is a natural mechanism for cell apoptosis. However, in the case of cancer cells, apoptosis becomes a potential mechanism for their survival and proliferation.

RETREG2 has been shown to inhibit the activity of FAM134A, which is responsible for the regulation of telomeres. By inhibiting the activity of FAM134A, RETREG2 has been shown to extend the telomeres in cancer cells, which can lead to the eventual death of the cells.

Current clinical trials

Currently, there are several clinical trials are being conducted to evaluate the potential of RETREG2 as a drug. One clinical trial is evaluating RETREG2 in combination with chemotherapy for the treatment of breast cancer. The trial is being conducted at the University of California, San Francisco and is led by Dr. Period Benxiongda.

Another clinical trial is evaluating RETREG2 in combination with radiation therapy for the treatment of lung cancer. The trial is being conducted at the University of California, Los Angeles and is led by Dr. Yudai Ohta.

Potential future directions

RETREG2 has a great potential as a drug target due to its unique mechanism of action. As mentioned earlier, RETREG2 selectively binds to the FAM134A protein, which is a key regulator of the telomeres. Telomeres are composed of a repeated sequence of DNA, which continuously gets shorter as the chromosome ages. When telomeres become too short, a cell may undergo a process called apoptosis, which is a natural mechanism for cell apoptosis. However, in the case of cancer cells, apoptosis becomes a potential mechanism for their survival and proliferation.

In the future, RETREG2 may be used in combination with chemotherapy and/or radiation therapy for the treatment of various types of cancer. Additionally, RETREG2 may also be used in the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.

Conclusion

RETREG2 is a potential drug target (or biomarker) due to its unique mechanism of action. As mentioned earlier, RETREG2 selectively binds to the FAM134A protein, which is a key regulator of the telomeres. Telomeres are composed of a repeated sequence of DNA, which continuously gets shorter as the chromosome ages. When telomeres become too short, a cell may undergo a process called apoptosis, which is a natural mechanism for cell apoptosis. However, in the case of cancer cells, apoptosis becomes a potential mechanism for their survival and proliferation.

Currently, there are several clinical trials are being conducted to evaluate the potential of RETREG2 as a drug. The combination of RETREG2 with chemotherapy and/or radiation therapy may be a promising approach for the treatment of various types of cancer in the future.

Protein Name: Reticulophagy Regulator Family Member 2

Functions: Endoplasmic reticulum (ER)-anchored autophagy regulator which exists in an inactive state under basal conditions but is activated following cellular stress (PubMed:34338405). When activated, induces ER fragmentation and mediates ER delivery into lysosomes through sequestration into autophagosomes via interaction with ATG8 family proteins (PubMed:34338405). Required for collagen quality control in a LIR motif-independent manner (By similarity)

More Common Targets

RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2